Summit Therapeutics

Summit Therapeutics

Summit is a biopharmaceutical oncology company focused on resolving serious unmet medical needs. Summit’s compound, ivonescimab, is a potential first-in-class bispecific antibody combining the effects of immunotherapy via anti-PD-1 with anti-angiogenesis effects of anti-VEGF in a single molecule. Ivonescimab displays cooperative binding to these targets with increased avidity in the tumor microenvironment. Summit’s Phase III NSCLC trials: NCT06396065, NCT05899608, NCT06767514. Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s NMPA.

Lung Cancer, Metastatic Disease, Antibodies, Biotechnology, Clinical Trials, Immunotherapy, Pharmaceutical

Yes